Pages

Saturday 6 October 2012

Abatacept-Orencia



Abatacept-Orencia


Generic Name :: Abatacept

Brand Name ::   Orencia



  


  • Prescribed For

 This medication is a synthetic protein, prescribed for adult rheumatoid arthritis, and juvenile idiopathic arthritis. Abatacept  will only be prescribed if patients’s  arthritis is active and he/she have tried methotrexate and another disease modifying anti-rheumatic drug (DMARD) such as sulfasalazine or leflunomide.










  • Preparation::

Powder for Injection: 250 mg. Prefilled Syringe: 125 mg/ml.




                                     




  • Storage:  





This medicine should be refrigerated between 2-8 C (36-46 F). 




  • Dosing


·         It is usually given in a doctor's office every 2 weeks for the first three doses and then every 4 weeks. It will take about 30 minutes for patients  to receive his/her  entire dose of abatacept.




.

                                                     

  •  Side effects
 
·       

  • ·         Nausea
  • ·         Dizziness
  • ·         Heartburn
  •            Headache
  • ·         Runny nose
  • ·         Sore throat
  •            Back pain
  • ·         Arm or leg pain
  • ·         Hives
  • ·         Shortness of breath
  • ·         Fever, chills, and other signs of infection
  • ·         Dry cough that doesn't go away 
  • ·         Skin rash
  • ·         Itching
  • ·         Swelling of the eyes, face, lips, tongue, or throat
  • ·         Difficulty breathing or swallowing
  •           Weight loss 
  •           Requent urination or sudden need to urinate right away
  • ·         Burning during urination
  • ·         Cellulitis (red, hot, swollen area on the skin) 
  •            Night sweats


  •  About ABATACEPT / ORENCIA

 ORENCIA/ABATACEPT  is a soluble fusion protein. It consists of the extracellular domain of human cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) linked to the modified Fc (hinge, CH2, and CH3 domains) portion of human immunoglobulin G1 (IgG1). This medicine  is produced by recombinant DNA technology in a mammalian cell expression system. It blocks the activity of T-cells, which causes swelling and joint damage in people with arthritis condition.








  • More information 

 

 





No comments:

Post a Comment